
Opinion|Videos|January 29, 2025
Monitoring Patients Transitioning From Obeticholic Acid
Panelists discuss how transitioning patients from obeticholic acid to seladelpar or elafibranor requires close monitoring of liver biochemistry, pruritus severity, medication adverse effects, and quality of life measures while providing clear patient education about expected timeline for symptom improvement and potential adjustment periods.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What key monitoring parameters should be prioritized when transitioning a patient from obeticholic acid to either seladelpar or elafibranor, especially during the initial stages of therapy?
- How should clinicians counsel patients on the expected changes in symptom management and potential side effects when transitioning from obeticholic acid to another PBC therapy?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
2
From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
3
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
4
FDA Grants Orphan Drug Designation to Zavabresib for the Treatment of Myelofibrosis
5





















